Molecular Fingerprints of Borderline Changes in Kidney Allografts Are Influenced by Donor Category

Hrubá, Petra; Krejčík, Zdeněk; Merkerová, Michaela Dostálová; Kléma, Jǐŕı; Stránecký, Viktor; Slatinska, Janka; Malušková, Jana; Honsová, Eva; Viklický, Ondřej

doi:10.3389/fimmu.2020.00423

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The upregulation of CCL13 expression is a result of pro-inflammatory cytokines in response and plays an important role in monocyte/macrophage recruitment and retention in renal inflammation ( 10 ). In addition, kidney donor quality significantly affects renal transplantation outcomes, such as recipients of kidney donors from the elderly who exhibit low post-transplant renal function and short graft lifespan; a single-center, retrospective, observational study showed that compared to standard criteria donors and living donors, elderly and expanded criteria donors have upregulated CCL13 at the transcriptional level and may be involved in post-transplant renal inflammation and renal function impairment ( 77 ).…”

Section: Ccl13 and Renal Diseasesmentioning

confidence: 99%

CCL13 and human diseases

Dai

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

CCL13/MCP-4 belongs to the CC chemokine family, which induces chemotaxis in many immune cells. Despite extensive research into its function in numerous disorders, a thorough analysis of CCL13 is not yet accessible. The role of CCL13 in human disorders and existing CCL13-focused therapies are outlined in this study. The function of CCL13 in rheumatic diseases, skin conditions, and cancer is comparatively well-established, and some studies also suggest that it may be involved in ocular disorders, orthopedic conditions, nasal polyps, and obesity. We also give an overview of research that found very little evidence of CCL13 in HIV, nephritis, and multiple sclerosis. Even though CCL13-mediated inflammation is frequently linked to disease pathogenesis, it’s fascinating to note that in some conditions, like primary biliary cholangitis (PBC) and suicide, it might even act as a preventative measure.

show abstract

Section: Ccl13 and Renal Diseasesmentioning

confidence: 99%

CCL13 and human diseases

Dai

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…ECD-related transcripts were likely increased by already occurred vascular changes compared to SCD group, and, similarly in SCD group, by longer ischemia compared with LD group. Therefore, chronic vascular changes and cold ischemia time enhance inflammation and thus contribute to poor outcomes for these grafts [57].…”

Section: Transcriptomics/genomicsmentioning

confidence: 99%

A Review of Current and Emerging Trends in Donor Graft-Quality Assessment Techniques

Warmuzińska

Łuczykowski

Bojko

2022

JCM

View full text Add to dashboard Cite

The number of patients placed on kidney transplant waiting lists is rapidly increasing, resulting in a growing gap between organ demand and the availability of kidneys for transplantation. This organ shortage has forced medical professionals to utilize marginal kidneys from expanded criteria donors (ECD) to broaden the donor pool and shorten wait times for patients with end-stage renal disease. However, recipients of ECD kidney grafts tend to have worse outcomes compared to those receiving organs from standard criteria donors (SCD), specifically increased risks of delayed graft function (DGF) and primary nonfunction incidence. Thus, representative methods for graft-quality assessment are strongly needed, especially for ECDs. Currently, graft-quality evaluation is limited to interpreting the donor’s recent laboratory tests, clinical risk scores, the visual evaluation of the organ, and, in some cases, a biopsy and perfusion parameters. The last few years have seen the emergence of many new technologies designed to examine organ function, including new imaging techniques, transcriptomics, genomics, proteomics, metabolomics, lipidomics, and new solutions in organ perfusion, which has enabled a deeper understanding of the complex mechanisms associated with ischemia-reperfusion injury (IRI), inflammatory process, and graft rejection. This review summarizes and assesses the strengths and weaknesses of current conventional diagnostic methods and a wide range of new potential strategies (from the last five years) with respect to donor graft-quality assessment, the identification of IRI, perfusion control, and the prediction of DGF.

show abstract

“…Although most studies have examined complement activation in standard DBD donors, intuitively, the degree of inflammation and thus complement activation may be more profound in DCD and extended criteria donors. Accordingly, comparisons of transcriptional profiles and histology have shown increased activation of inflammatory chemokines, complement, and coagulation in DCD and extended criteria kidneys, compared to standard criteria donors ( 34 , 35 ).…”

Section: The Role Of Complement System In Irimentioning

confidence: 99%

Complement-targeting therapeutics for ischemia-reperfusion injury in transplantation and the potential for ex vivo delivery

DeLaura

Gao²,

Anwar³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Organ shortages and an expanding waitlist have led to increased utilization of marginal organs. All donor organs are subject to varying degrees of IRI during the transplant process. Extended criteria organs, including those from older donors and organs donated after circulatory death are especially vulnerable to ischemia-reperfusion injury (IRI). Involvement of the complement cascade in mediating IRI has been studied extensively. Complement plays a vital role in the propagation of IRI and subsequent recruitment of the adaptive immune elements. Complement inhibition at various points of the pathway has been shown to mitigate IRI and minimize future immune-mediated injury in preclinical models. The recent introduction of ex vivo machine perfusion platforms provides an ideal window for therapeutic interventions. Here we review the role of complement in IRI by organ system and highlight potential therapeutic targets for intervention during ex vivo machine preservation of donor organs.

show abstract

Molecular Fingerprints of Borderline Changes in Kidney Allografts Are Influenced by Donor Category

Cited by 5 publications

References 29 publications

CCL13 and human diseases

CCL13 and human diseases

A Review of Current and Emerging Trends in Donor Graft-Quality Assessment Techniques

Complement-targeting therapeutics for ischemia-reperfusion injury in transplantation and the potential for ex vivo delivery

Contact Info

Product

Resources

About